PACAP and its receptors in cranial arteries and mast cells

Inger Jansen-Olesen 1,2* and Sara Hougaard Pedersen 1

Abstract

Background: In migraineurs pituitary adenylate cyclase activating peptide 1–38 (PACAP1–38) is a potent migraine provoking substance and the accompanying long lasting flushing suggests degranulation of mast cells. Infusion of the closely related vasoactive intestinal peptide (VIP) either induces headache or flushing. This implicates the pituitary adenylate cyclase activating peptide type I receptor (PAC1) to be involved in the pathophysiology of PACAP1–38 provoked headaches. Here we review studies characterizing the effects of mainly PACAP but also of VIP on cerebral and meningeal arteries and mast cells.

Discussion: PACAP1–38, PACAP1–27 and VIP dilate cerebral and meningeal arteries from several species including man. In rat cerebral and meningeal arteries the dilation seems to be mediated preferably via vasoactive intestinal peptide receptor type 1 (VPAC1) receptors while, in human, middle meningeal artery dilation induced via vasoactive intestinal peptide receptor type 2 (VPAC2) receptors cannot be ruled out. PACAP1–38 is a strong degranulator of peritoneal and dural mast cells while PACAP1–27 and VIP only have weak effects. More detailed characterization studies suggest that mast cell degranulation is not mediated via the known receptors for PACAP1–38 but rather via a still unknown receptor coupled to phospholipase C.

Conclusion: It is suggested that PACAP1–38 might induce migraine via degranulation of dural mast cells via a yet unknown receptor.

Keywords: Migraine, PACAP, VIP, Cerebral artery, Middle meningeal artery, Mast cells

Review

Migraine is number six in WHO list of all diseases causing disability [1] and it is the third most costly neurological disorder in Europe [2]. Even though the triptans revolutionized the acute treatment of migraine, a huge unmet need for better or different acute treatments exists [3]. An interesting molecule in this aspect is pituitary adenylate cyclase activating peptide (PACAP), which exists in the body as 38- and 27- amino acid peptides [4, 5]. These peptides partly share receptors with their family member vasoactive intestinal peptide (VIP) [6]. In migraineurs, elevated levels of PACAP1–38 were found in blood sampled from the external jugular vein [7] and cubital vein [8] during migraine attacks. Infusion of PACAP1–38 provokes immediate headache in 11 out of 12 migraine patients, 7 of these patients develop delayed migraine attacks. In all 12 healthy subjects an immediate headache was experienced, two of these subsequently reporting migraine-like symptoms [9, 10]. Interestingly, VIP only induces a mild headache and no migraine-like attacks in migraineurs [11]. These findings point towards the PAC1 receptor, which is targeted by PACAP with much higher affinity than VIP, as a key target for migraine treatment. In this review we describe studies characterizing the receptors upon which PACAP and VIP mediate dilation of intracranial arteries and degranulation of peritoneal and dural mast cells.

Pituitary adenylate cyclase activating peptide

Pituitary adenylate cyclase activating peptide (PACAP) is a highly conserved signaling peptide of identical structure in mammals including human, sheep, rat and mouse [12]. It is a member of the glucagon/secretin superfamily of peptides [6, 13, 14] and is endogenously...
present in two isoforms namely; PACAP1–38 and the C-terminal truncated version PACAP1–27. High concentrations of PACAP1–38 are found in brain and in testis. Especially the hypothalamus but also other brain regions contain considerable amounts of PACAP1–38. PACAP1–27 is considerably less abundant in these regions as compared to PACAP1–38 [4]. A related member of the glucagon/secretin superfamily is the 28 amino acid peptide, VIP that shares 68% homology with PACAP1–27 from the N-terminal end. PACAP and VIP are signaling molecules widely distributed throughout the central and peripheral nervous system [6, 13] involved in e.g. regulation of circadian rhythm [15], neuroprotection [16, 17], inflammation and pain perception [18, 19]. PACAP-immunoreactivity (−IR) and VIP-IR co-localize in nerve fibers innervating cerebral vessels and parasympathetic ganglia [20–24] and in dura mater where it occasionally co-localizes with calcitonin gene-related peptide (CGRP) [25]. In trigeminal ganglion, PACAP-IR co-localizes with CGRP-IR neurons, while only PACAP-IR is found in satellite glial cells [26–28]. In the spinal trigeminal nucleus PACAP-IR co-localizes with CGRP-IR in nerve fibers in laminae I and II [26, 29].

PACAP receptors

PACAP and VIP partially share receptors and PACAP signal transduction is mediated through three high-affinity G protein-coupled receptors namely pituitary adenylate cyclase activating peptide type I receptor (PAC1), vasoactive intestinal peptide receptor type 1 (VPAC1), and vasoactive intestinal peptide receptor type 2 (VPAC2). The affinities of PACAP1–38 and PACAP1–27 are equal to that of VIP for VPAC1- and VPAC2-receptors, whereas the affinity of PACAP1–38 and PACAP1–27 for the PAC1 receptor (PAC1-R) is about 1000-fold higher than that of VIP [6, 19, 30] (Fig. 1). The potent headache provoking property of PACAP1–38 (Fig. 1) is in comparison with the poor effect of VIP [11], suggests PAC1-R to be an interesting target for migraine treatment.

In human cerebral and middle meningeal arteries, messenger RNA (mRNA) for VPAC1, VPAC2 and PAC1 receptors has been identified [31, 32]. In rat, mRNA of the same three receptors was shown by qPCR in middle meningeal arteries [33] and in situ hybridization to be localized in smooth muscle cells of middle cerebral arteries, basilar arteries and middle meningeal arteries [34]. Immunohistochemistry with antibodies for the VPAC1 receptor shows its presence in the smooth muscle cells of rat cerebral arteries [24]. In rat trigeminal ganglion and spinal trigeminal nucleus all three receptors are detected at the mRNA level [26, 33].

Cranial arteries and migraine

In the 1940’s the genesis of migraine pain was attributed to meningeal and cerebral arteries, as it was reported that electrical stimulation of these arteries evoked nausea and ipsilateral pain, localized to the area in and around the eye, including the forehead and temple [35, 36]. The perivascular proximity of nociceptive afferents [37, 38], the pulsating nature of migraine headache (in 80% of patients) aggravating with physical activity [39] as well as pain and nausea induction during arterial stimulation [36], have all been interpreted as strong indicators of a vascular component of migraine pathogenesis. However, accumulating evidence has challenged the theory of migraine as a vascular disease. Migraine-provoking substances are strong vasodilators [10, 40–43]. However, not all vasodilatory compounds provoke accompanying headache [11, 44]. It was recently shown that spontaneous migraine attacks in patients are accompanied by dilation of the pain sensitive middle cerebral and internal carotid arteries whereas no dilation of dural and extracranial arteries are observed [45].

The effect of PACAP on cerebral arteries

**In vitro**

The relaxant effect of PACAP has been studied on isolated cerebral arteries from several species including humans. The potency of PACAP1–38 and PACAP1–27 given as pD2 values (the negative logarithm to base 10 of the concentration of a drug that gives half-maximal response) are in most specimens around 8 (Table I). In
cat the potency and efficacy for VIP were somewhat higher than for PACAP1–38 and PACAP1–27 [46], while no difference in potency was found between PACAP1–27 and VIP in rabbit [23]. PACAP1–27 is less potent as a dilator of human cerebral arteries than calcitonin gene-related peptide (CGRP) and VIP (Fig. 2). Comparing data from two different studies performed in human cerebral arteries, one with PACAP1–38 and the other using PACAP1–27, the relaxations were of the same potency, but PACAP1–38 has a lower efficacy than PACAP1–27 (Table 1) [47, 48]. This observation was also made in rat using pressurized arteriography [47] but not in a wire myography study [34]. However, a direct comparison of PACAP1–38 and PACAP1–27 induced effects on human cerebral arteries in parallel experiments has yet to be performed. Blockade experiments suggest VPAC1 receptors to be of importance for PACAP and VIP induced relaxation of rat middle cerebral and basilar arteries [34].

**In vivo**

No studies describe the *in vivo* effect of PACAP on cerebral arteries after i.v. infusion to laboratory animals. The reason for this is most probably due to the fact that PACAP has to cross the blood–brain barrier to reach its receptors in the smooth muscle cells of cerebral arteries. A transport mechanism for PACAP1–38 has been described, which is dependent on the peptide transport system-6 (PTS-6) [49]. However, only a small percentage (0.053%) of PACAP-38 enters the brain after intravenous administration [50]. If a dilation of cerebral arteries is achieved together with a fall in mean arterial blood pressure the interpretation of the results is made complicated due to activation of autoregulatory mechanisms leading to dilation of cerebral arteries [51]. To avoid confusion about dilation of cerebral arteries, pharmacological substances can be infused via an indwelling catheter in the common carotid artery (i.c.), which allows cerebral arteries to be studied without systemic effects [52]. However, no studies has to date been performed to investigate the effect of PACAP1–38 on cerebral arteries after i.c. infusion. In human experimental studies PACAP1–38 infusion in healthy volunteers [53] and migraine patients [54] showed a minor short-lasting dilation of middle cerebral arteries. The measurement of middle cerebral artery diameter in these studies was calculated from blood velocity in the middle cerebral artery and was therefore indirect. In another study, no change in mean circumference of middle cerebral artery was found after infusion of PACAP1–38. Here magnetic resonance angiography was used, which is a more direct way to measure the artery diameter and is superior to measurement of blood velocity [9].

**The effect of PACAP on middle meningeal arteries**

**In vitro**

To the best of our knowledge only two studies have been published describing vascular responses of isolated middle meningeal arteries from animals. In the first study, administration of PACAP1–38, PACAP1–27, and VIP to pre-contracted rat arterial segments did not cause any significant effect. Confirming the viability of the preparation, treatment with CGRP of the same arterial segments caused a 100% relaxation of the pre-contraction [34]. In the second study, rat middle meningeal arteries were mounted in a pressurized myograph system. In concentrations as low as 1–1000 pM, PACAP1–38 caused dilation of middle meningeal arteries that were blocked by the PAC1 receptor antagonist PACAP6-38 [55] (Fig. 3). It was suggested that PACAP1–38 affected middle meningeal artery tone by acting on a combination of two splice variants of the PAC1 receptor, namely the PAC1null and PAC1Hop1 receptor isoforms. Stimulation of PAC1 receptor causes in turn activation of the cyclic adenosine monophosphate/protein kinase A pathway leading to the opening of adenosine triphosphate sensitive potassium channels [56].

In man, PACAP1–38 and VIP induced only a weak relaxation of isolated middle meningeal arteries [31, 57]. VIP had a somewhat more potent effect on dilation than PACAP1–38. Neither the PAC1 antagonist PACAP6–38 nor the VPAC1 antagonist PG97–269 were able to block the PACAP1–38 induced relaxation suggesting the effect to be mediated via VPAC2 receptors [31].

**In vivo**

The genuine closed cranial window model has been used to study the effect of PACAP1–38, PACAP1–27, and
VIP on rat middle meningeal artery in vivo. When given as a bolus i.v. infusion to anaesthetized rats, a maximal dilation of ~60% was found for VIP and PACAP1–27, while the efficacy of PACAP1–38 was somewhat lower, with a dilation of ~45%. Interestingly, the pD2 value of ~6 (in g/kg) for PACAP1–38 indicated a higher sensitivity of the middle meningeal artery as compared to PACAP1–27 with a pD2 value of ~5.5 [33]. In the presence of VPAC1 receptor antagonist (PG97–269) the response to PACAP1–38 but not to VIP was significantly decreased [33]. When given alone PACAP6–38 induced a slight dilation, but no significant inhibition of PACAP1–38 induced dilation of middle meningeal arteries was observed [33]. All together suggesting PACAP1–38 induced dilation of middle meningeal artery to be mediated via VPAC1 receptors. In another study, PG97–269 did not inhibit VIP and PACAP1–38 induced dilation of middle meningeal arteries. On the other hand, the VPAC1/VPAC2 antagonist VIP6–28 significantly inhibited VIP and PACAP1–38 induced dilation, suggesting VPAC2 receptors to be responsible [58]. This is in support of the findings in human meningeal arteries [31]. Thus, controversy exists whether VIP and PACAP induced dilation of rat meningeal arteries are mediated via VPAC1 or VPAC2 receptors.

Intra carotid artery administration of PACAP1–38 induces an ED50 (the dose of a drug that gives half-maximal response) response in dural arteries at ten times lower concentrations of PACAP1–38 than after i.v. infusion [52]. Also, the maximum change in artery diameter from baseline was around 75% when given i.c. and 50% when given i.v. [52]. Increasing doses of PACAP1–38, PACAP1–27, and VIP administered as bolus i.c. infusion exhibited pD2-values of 6.7, 6.5, and 6.2, respectively. The maximum responses to PACAP1–38 and PACAP1–27 were around 105% (change from baseline) and VIP around 75% (Fig. 4) [59]. Because of variations

### Table 1 Data on relaxant responses induced by PACAP1–38, PACAP1–27 and VIP performed in vitro on cerebral arteries from different species

| Species | PACAP1–38 | PACAP1–27 | VIP |
|---------|-----------|-----------|-----|
|         | pD2       | Emax     | n   | pD2       | Emax     | n   | pD2       | Emax     | n   |
| Cat     | 7.9 ± 0.2 | 24 ± 9   | 7   | 7.7 ± 0.4 | 31 ± 5   | 7   | 8.3 ± 0.1 | 68 ± 8   | 8   |
| Rabbit  | n.d.      | n.d.     | –   | 8.0 ± 0.1 | 53 ± 11  | 6   | 8.1 ± 0.1 | 73 ± 5   | 6   |
| Rat     | 7.8 ± 0.1 | 48 ± 7   | 8   | 8.0 ± 0.1 | 51 ± 3   | 8   | 8.0 ± 0.2 | 52 ± 8   | 7   |
| Rat²A   | 7.6 ± 0.2 | 10 ± 1   | 5   | 7.8 ± 0.1 | 25 ± 1   | 4   | 8.7 ± 0.1 | 28 ± 1   | 4   |
| Human   | n.d.      | n.d.     | –   | 8.2 ± 0.2 | 84 ± 9   | 4   | 8.8 ± 0.4 | 84 ± 9   | 7   |
| Human   | 8.4 ± 0.5 | 27 ± 8   | 5   | n.d.      | n.d.    | –   | 8.1 ± 0.1 | 57 ± 9   | 5   |

Data is given as pD2 (negative log concentration inducing half maximum relaxant response), Emax (maximum relaxant response in % of pre-contraction or maximum dilatory capacity), n = number of experiments.

²Pressurized arteriography abluminal application

*PACAP1–27 was used because it induced a stronger response than PACAP1–38

---

**Fig. 3** Low picomolar concentrations of PACAP, but not VIP, dilate isolated pressurized rat middle meningeal arteries. Cumulative concentrations of PACAP and VIP were administered to arterial segments pressurized to 40 mmHg ex vivo. Arteries were exposed to aCSF containing each concentration of PACAP1–38 or VIP for 20 min. Dilation to PACAP1–38 or VIP are expressed as percentage of maximum dilation obtained in the presence of Ca2+−free artificial CSF containing 100 μM of the calcium channel blocker diltiazem and 1 μM of the adenylyl cyclase activator forskolin. p < 0.05 by unpaired t test, n = 4. From Syed et al. [55]

**Fig. 4** Effects of increasing doses (i.c.) of PACAP1–38, PACAP1–27 and VIP on middle meningeal artery diameter in the genuine closed cranial window model. Mean values ± SEM from 5 to 7 animals. Adapted from Bhatt et al. [59]
between animals no significant differences between PACAP1–38, PACAP1–27 and VIP responses were observed.

Mast cells and migraine

**Mast cells**

Mast cells were first described in the late nineteenth century, but it was not until the 1950’s that part of their biological contribution to inflammatory allergic diseases became known through the discovery of histamine release. Mast cells contain vesicles comprising numerous inflammatory and vasodilatory substances (Fig. 5) and undergo degranulation upon activation by exogenous allergens or endogenous stimuli [60]. Mast cells are derived from pluripotent hematopoietic CD34+ stem cells in the bone marrow and circulate in the blood as progenitors before they acquire a mature phenotype in the microenvironment of their target tissue [61]. They are embedded in various tissues throughout the body and derive into either of two subtypes as referred to as mucosal or connective tissue type mast cells. The local cytokine environment conditions their subtype, but they hold an ability to adapt and change phenotype if needed [62, 63]. Mast cells embedded in skin, peritoneum, and dura mater are all of the connective tissue type, and thus peritoneal mast cells can potentially be used as a model for dura mater mast cells [64].

Two different signaling pathways leading to degranulation have been identified, namely the antigen and the basic secretagogue. The antigen pathway comprises stimulation through cross-linking with the high-affinity immunoglobulin E (IgE) receptors, FceRI, and mast cells release their mediators to the local environment. Basic secretagogues stimulate mast cells to degranulate via G protein-dependent activation of phospholipase C. However, they can also be stimulated to degranulate via mechanical, thermal, or even receptor-independent mechanisms [65].

**Clinical implications of mast cell-involvement in migraine**

A correlation between mast cell function and migraine has been clinically implicated by significantly elevated plasma histamine levels in migraine patients, both during attacks and in interictal periods [66, 67]. For migraineurs there is a high comorbidity to histamine-driven conditions like allergic rhinitis, asthma, and food allergy [68–71] as compared to the general population [72]. Histamine-infusion to migraineurs induced an immediate headache during infusion, followed by a genuine migraine attack several hours later. This can be abolished by pretreatment with the histamine-receptor 1 (H1) antagonist, mepyramine [73]. However, histamine release alone is not responsible for spontaneous migraine attacks, as histamine-receptor H1 and H2 blockade is a poor prophylaxis for migraine sufferers [73, 74], indicating a discrepancy between genuine migraine attacks as compared to histamine-provoked attacks. Stimulation of histamine H3 receptors have been suggested to be involved in a negative feedback loop causing inhibition of histamine release from mast cells and C-fiber nerve endings [75]. The histamine catabolite N⁰-methylhistamine, that is about 3 times more active as an agonist on the H3 receptor, was found to be significantly better than placebo after prophylactic treatment twice a week for
12 weeks [75]. These findings are somewhat surprising, considering that H1- and H2 receptor antihistamines have not been effective in treating migraine [76].

In addition to histamine, mast cells release several chemical mediators such as prostaglandin I₂ (PGI₂), that has been shown to cause activation and sensitization of meningeal sensory afferents [77, 78] and to induce immediate headache in migraine patients and non-migraineurs as well as migraine-like attacks in migraineurs [43, 79]. Glyceryl trinitrate (GTN) is a potent migraine provoking substance that in low doses causes degranulation of dural mast cells after i.v. infusion to awake as well as anaesthetized rats [80, 81]. PACAP, but not VIP, has been shown to induce migraine headache as well as mast cell degranulation [10, 11, 82]. Thus, given their pro-inflammatory properties and their dense population in dura mater, mast cells are suggested to be involved in the pathophysiological processes leading to migraine [83–85].

Characterization of PACAP-induced mast cell degranulation

The mast cell degranulating effect of PACAP was first shown in human skin biopsies [86]. Single challenges with PACAP1–38, PACAP1–27, and VIP caused significant release of histamine peaking at 4 min after skin challenge. The release of histamine was significantly higher for VIP and PACAP1–27 as compared to PACAP1–38 [86]. In mice an intradermal injection of PACAP1–38 induced oedema and significant degranulation of mast cells [87]. In a more detailed study, mast cell degranulation induced by PACAP analogues, including both PAC1 receptor agonists and antagonists, was characterized in isolated rat peritoneal mast cells. PACAP1–38, PACAP1–27, VIP, PACAP6–38, PACAP16–38, and PACAP28–38 induced a concentration-dependent degranulation of the mast cells (Fig. 6). The compounds tested divided in two distinct groups, the efficient degranulators being PACAP1–38, PACAP6–38, and PACAP16–38 with pEC₅₀ values between 6.6 and 6.2; interestingly, the PAC1 receptor antagonist PACAP6–38 is a member of this group. The other group consisted of weaker degranulators being PACAP1–27, VIP, and PACAP28–38 with pEC₅₀ values between 5.5 and 4.8. Furthermore both, the PAC1 receptor agonist maxadilan, a 61–amino acid peptide with no significant sequence homology to PACAP [23], and the PAC1 receptor selective antagonist max.d.4, a modified fragment of maxadilan, showed no mast cell degranulating effects when applied at a concentration of up to 10⁻⁵ M [82]. These findings all suggest a PAC1 receptor independent mast cell degranulation and are further supported by a still unpublished study from our group where the PAC1 receptor antagonist M65 (another modified fragment of Maxadilan) failed to inhibit PACAP1–38 induced mast cell degranulation. Inhibition of intracellular mechanisms demonstrated that the phospholipase C inhibitor U-73122 significantly inhibited PACAP1–38- but not PACAP1–27- and VIP-induced mast cell degranulation (Fig. 7). The adenylyl cyclase inhibitor SQ 22536 has no effect on mast cell degranulation induced by either of the peptides. When taken together, the difference in potency between mast cell degranulating effects of PACAP1–38 and PACAP1–27 known to be equipotent on PAC1 receptors, the potent mast cell degranulating properties of the PAC1 receptor antagonist PACAP6–38 and the lack of inhibitory effect of M65 on PACAP1–38 induced mast cell degranulation, all suggest that degranulation is not mediated via the PAC1 receptor in rat [82].

The role of PACAP1–38 induced mast cell degranulation on dural artery dilation

In healthy human volunteers PACAP1–38 was given as a 20 min infusion leading to vasodilation of the middle meningeal artery for up to five hours after infusion [10]. PACAP1–38 has an elimination half-life of 3.5 to 10 min [53, 88], hence the delayed effect cannot be attributed to a direct vascular effect of PACAP1–38, but rather to a cascade of events triggered by PACAP1–38. The
strong degranulatory effect of PACAP1–38 on rat mast cells [82] and the dense population of mast cells found in apposition to dural arteries (Fig. 8) inspired our group to perform a set of experiments investigating the role of mast cell degranulation in middle meningeal artery dilation using the rat closed cranial window model. In these experiments one group of rats received repeated treatment with the secretagogue Compound 48/80, while the other group received vehicle. At the time of experiment, 4–5 days after the treatment, the mast cells were depleted of their granules (Fig. 8) [59]. In control rats a 20 min infusion of PACAP1–38, PACAP1–27, and CGRP but not VIP caused a significant increase in middle meningeal artery diameter. The response to CGRP returned to normal within 10 min after the end of infusion, while vasodilation induced by PACAP1–38 and PACAP1–27 showed a slower recovery. Fifty minutes after PACAP1–38 infusion, but not after PACAP1–27 infusion, the middle meningeal artery was still significantly dilated (Fig. 9) [59].

The PAC1 receptor antagonist PACAP6–38 exhibits potent mast cell degranulating properties [82], but without direct vascular effects. When infused over 20 min no significant change in middle meningeal artery diameter is observed. However, after termination of the infusion the artery starts to dilate and dilation reaches significance at 30 min, lasting until the end of experiment 50 min after the infusion. Chronic depletion of mast cells attenuates the responses to PACAP1–38 and PACAP1–27 and abolishes the delayed PACAP6–38 induced dilation (Fig. 9) [59]. This suggests that PACAP1–38 causes dilation of middle meningeal arteries partly due to mast cell degranulation. These effects might be responsible for long-lasting flushing and delayed migraine attacks observed after PACAP1–38 infusion.

Taking the results of all the described studies together, it is interesting to note that the PAC1 receptor
antagonist PACAP6–38 is as potent a mast cell degranulator as PACAP1–38 and that the effect seems to be mediated via a non-PAC1 receptor. Furthermore, the weak mast cell degranulating effects of VIP suggest that VPAC1 and VPAC2 receptors are not involved. Though, PACAP6–38 is widely used as a PAC1 receptor antagonist it should be kept in mind that it has agonistic mast cell degranulating properties similar to that of PACAP1–38 [82] and thus hypothetically PACAP6–38 might cause hypersensitivity via this mechanism. The PAC1 receptor antagonists M65 and max.d.4 don’t share the mast cell depleting properties of PACAP6–38 and therefore should be preferred in studies characterizing the effects of PACAP on durally evoked hypersensitivity. The stimulatory effect of PACAP6–38 on a non-PAC1 receptor is supported by a study performed in a primary culture of trigeminal ganglion neurons from rat and mice in which, PACAP6–38, act as an agonist [89]. However, in this study the antagonists M65 (PAC1) and VIP6–28 (VPAC1 and VPAC2) share the agonistic features with PACAP6–38. The mast cell degranulation and migraine provoking effects of PACAP6–38 have not been investigated in humans. Presuming that the rank order of potency for these compounds to induce mast cell degranulation in humans equals that in rats, such a study would disclose if PACAP1–38 and PACAP6–38 have the same order of potency in headache provocation and if mast cell degranulation is involved in migraine pathophysiology. Such a study would also reveal if PACAP provoked migraine is induced by PAC1 receptors or via a yet unknown PACAP receptor.

**Conclusion**

The few studies involving pharmacological characterization of PACAP- and VIP-induced relaxant responses of cerebral arteries from animals suggest the involvement of VPAC1 receptors. The mechanism for PACAP1–38 to cross the blood–brain barrier seems to be insufficient for transporting PACAP into the smooth muscle layer of the cerebral arteries in concentrations high enough to induce vasodilation after i.v. infusion of PACAP1–38.

Though isolated rat dural arteries do not respond to PACAP or VIP in a wire myograph system, PACAP1–27, PACAP1–38, and VIP show equipotent effects in studies performed on human middle meningeal arteries *in vitro* and rat dural arteries in vivo. In man, blockade experiments with VPAC1 and PAC1 receptor antagonists, suggests the dilation to be mediated via VPAC2 receptors.
However, this assumption has not been confirmed by the use of selective antagonists for VPAC2 receptors. In rat, controversy exists whether VPAC1 or VPAC2 receptors are involved in PACAP1–38 induced meningeal artery vasodilation. As the PAC1 receptor has been suggested to be responsible for PACAP1–38 induced headache/migraine, the above described findings suggest PACAP1–38 induced headache/migraine not to be mediated via vascular responses. However, the extremely potent PAC1 receptor mediated effect of PACAP1–38 on middle meningeal arteries in a pressurized myograph system suggests a mechanism that can be involved in migraine pathophysiology. This finding was however, not observed in vivo after bolus or long term infusion with PACAP1–38 to rat or in vitro in wire myograph studies of human middle meningeal arteries.

Neurogenic inflammation involving degranulation of dural mast cells has been proposed to be part of the pathophysiological mechanisms of migraine. In rat, PACAP induces degranulation of peritoeal and dural mast cells via receptors coupled to phospholipase C. Long-term PACAP infusion causes middle meningeal artery dilation that partly is caused by degranulation of dural mast cells. Characterization of the responses suggests that the effect on mast cells is mediated via non-VPAC and –PAC1 receptors. Identifying such a receptor and a subsequent development of substances with selective antagonistic/inhibitory effect on this receptor, will open doors for more detailed studies on the role of mast cells in migraine pathophysiology. Another question to be answered is whether it is the PAC1 receptor or a still not identified receptor(s) that is (are) responsible for migraines provoked by PACAP.

Abbreviations
CGRP: Calcitonin gene-related peptide; ED50: The dose of a drug that gives half-maximal response; FcεRI: Immunoglobulin E (IgE) receptor; i.c.: Intra carotid artery; i.v.: Intravenous; mRNA: Messenger RNA; PAC1: Pituitary adenylate cyclase-activating polypeptide type I receptor; PACAP: Pituitary adenylate cyclase-activating polypeptide; pD2: Negative logarithm of the molar concentration producing the half maximum response; VIP: Vasoactive intestinal peptide; VPAC1: Vasoactive intestinal peptide (VIP) receptor type 1; VPAC2: Vasoactive intestinal peptide (MP) receptor type 2

Acknowledgements
This work was supported by Candys Foundation, Novo Nordisk Foundation and Lundbeck Foundation.

Authors’ contributions
U-O conceived and designed the review, drafted the manuscript and revised it for intellectual content. SHP revised the manuscript for intellectual content and provided essential comments to finalize the manuscript. Both authors read and approved the final manuscript.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 September 2017 Accepted: 9 November 2017

References
1. Vos T, Barber RM, Bell B, Bertozi-Villa A, Biryukov S, Bolliger I et al (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386(9995):743–800
2. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19(1):155–162
3. Tfelt-Hansen P, Olesen J (2012) Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 26(3):375–382
4. Arimura A, Somogyvári-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129(5):2787–2789
5. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the putative adenylyl cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170(2):634–648
6. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2002) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269–324
7. Zagami AS, Edvinsson L, Godštby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Tranl Neurol 1(2):1036–1040
8. Tuka B, Helyes Z, Markovics A, Bagoly T, Szocsányi J, Szabó N et al (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33(13):1085–1095
9. Amin FM, Ashgar MS, Guo S, Hougaard A, Hansen AE, Schytz HW et al (2012) Headache and prolonged dilation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32(2):140–149
10. Schytz HW, Birsk S, Wienceke T, Kruse C, Olesen J, Ashina M (2008) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(1):16–25
11. Rahmann A, Wienceke T, Hansen J, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal polypeptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28(3):226–236
12. Sherwood NW, Kruedel SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21(6):619–670
13. Fahrenkrug J (2006) PACAP—A multifaceted neuropeptide. Chronobiol Int 23(1):253–61
14. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61(3):283–357
15. Hannibal J, Fahrenkrug J (1995) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) gene by rat sertoligic ovarian cells. Regul Pept 55(1):111–115
16. Chen Y, Samal B, Hamelink CR, Xiang CC, Chen Y, Chen M et al (2006) Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept 137(1):4–19
17. Vaudry D, Hamelink C, Damadzic R, Eskin RL, Gonzalez B, Eiden LE, Endogenous PACAP (2005) Acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 26(12): 2513–2524
18. Dickinson T, Fleetwood-Walker S, Mitchell R, Lutz E (1997) Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31(2):175–185
19. Harmar AJ, Arimura A, Goesi I, Joumout L, Labunth M, Pisegna JR et al (1998) International Union of Pharmacology. VIII. Nomenclature of receptors for vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50(2):265–270
20. Edvinsson L, Elsid T, Suzuki N, Shimizu T, Jer-Fu Lee T (2001) Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 53(3):221–228
21. Mulder H, Uddman R, Moller K, Elks T, Ekbлад E, Alumets J et al (1995) Pituitary adenylate cyclase activating polypeptide is expressed in autonomic neurons. Regul Pept 59(1):121–128
22. Uddman R, Goadby P, Jansen I, Edvinsson L (1993) PACAP, a VIP-like peptide: Immunohistochemical localization and effect upon cat pupils and cerebral blood flow. J Cereb Blood Flow Metab 13(2):291–297
23. Dalggaard T, Hannibal J, Fahrenkrug J, Larsen CR, Ottesen BV (2003) PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 110(3):179–188
24. Fahrenkrug J, Hannibal J, Tams J, Georg B (2000) Immunohistochemical localization of the VIP1 receptor (vPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 20(8):1205–1214
25. Eftekhar S, Wartwine K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14(11):1289–1303
26. Jansen-Olesen I, Baun M, Amundtuk VR, Ramachandran R, Christophersen DV, Olesen J (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC 1 receptor. Neuropeptides 48(2):53–64
27. Mulder H, Uddman R, Moller K, Zhang Y-Z, Ekbland E, Alumets J et al (1994) Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63(1):307–312
28. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76(2):176–183
29. Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L (2002) Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22(11):2–112
30. Ciccarelli E, Svoboda M, De Neef P, DI Paolo E, Bollen A, Dubeaux C et al (1995) Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. Eur J Pharmacol 288(1–2):269–276
31. Chan KY, Baun M, Vries RD, van den Bogaerdt AJ, Dirven CM, Danser AHJ et al (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronar artery. Cephalalgia 31(2):181–189
32. Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 13(4):507–509
33. Boni L, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S (2009) The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 29(8):837–847
34. Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I (2011) Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur J Pharmacol 670(1):186–194
35. Kelm H, La Grange P, Olesen J, Jansen-Olesen I, Gupta S (2009) The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 29(8):837–847
36. Ray BS, Wolff HG (1940) Experimental studies on headache: pain-sensitive cranial and spinal meninges: morphology of nerve fiber terminals and their structural interaction. Microsc Res Tech 53(2):96–105
37. Miyake M, Langer RS, Zervos NA, Moskowitz MA (1981) Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 213(4504):228–230
38. Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–698
39. Iversen HK, Olesen J, Tøkt-Pedersen P (1989) Intravenous nitric oxide in migraine sufferers. Cephalalgia 13(9):395–399
40. Wingecke T, Olesen J, Ottesen PS, Ashina M (2008) Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139(1):106–116
41. Krause C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126(1):241–247
42. Thomsen LL, Iversen HK, Brinck TA, Olesen J (1993) Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 13(9):395–399
43. Van Lengerich H, Arndt T, Dehler C, Jansen-Olesen and Hougaard Pedersen
The Journal of Headache and Pain (2018) 19:16
67. Heatley R, Denburg J, Bayer N, Bienenstock J (1982) Increased plasma histamine levels in migraine patients. Clinical & Experimental Allergy 12(2): 145–149
68. Kemper R, Meijler W, Korf J, Ter Horst G (2001) Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 21(5):549–557
69. Mansfield LE, Vaughan T, Waller SF, Haverly RW, Ting S (1985) Food allergy and adult migraine: double-blind and mediator confirmation of an allergic etiology. Ann Allergy 55(2):126–129
70. Peng Y-H, Chen K-F, Kao C-H, Chen H-J, Hsia T-C, Chen C-H et al (2016) Risk of migraine in patients with asthma: a nationwide cohort study. Medicine 95(9)
71. Wilson C, Kerker J, Barnes H, O’Malley M (1980) The clinical features of migraine as a manifestation of allergic disease. Postgrad Med J 56(659):617–621
72. Ku M, Silverman B, Prifti N, Ying W, Persaud Y, Schneider A (2006) Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 97(2):226–230
73. Lassen LH, Thomsen LL, Olesen J (1995) Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 6(1): 1475–1479
74. Anthony M, Lord G, Lance J (1978) Controlled trials of cimetidine in migraine and cluster headache. Headache 18(5):261–264
75. Millan-Guerrero RO, Isais-Millan R, Bernardin TH, Tene CE (2006) Nα-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. The Canadian journal of neurological sciences. J Can Sci Neurol 33(2):195–199
76. Alstadhaug KB (2014) Histamine in migraine and brain. Headache 54(2): 246–259
77. Strassman A, Raymond S, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384(6609):560
78. Zhang X-C, Strassman AM, Burstein R, Levy D (2007) Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 322(2):806–812
79. Wieniecke T, Olesen J, Ashina M (2011) Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D2 (PGD2). Cephalalgia 31(1):65–76
80. Pedersen SH, Ramachandran R, Amrutkar DV, Petersen S, Olesen J, Jansen-Olesen I (2015) Mechanisms of glyceryl trinitrate provoked mast cell degranulation. Cephalalgia 35(14):1287–1297
81. Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, del Rio MS, Letourneau R et al (2001) Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 124(12):2490–2502
82. Baun M, Pedersen MHF, Olesen J, Jansen-Olesen I (2012) Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 32(4):337–345
83. Levy D (2009) Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 13(3):237–240
84. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM (2007) Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130(1):166–176
85. Levy D, Burstein R, Strassman AM (2006) Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 46s1
86. Ødum L, Petersen L, Skov P, Ebskov L (1998) Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 47(12):488–492
87. Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK (1999) Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept 82(1):65–69
88. Li M, Maderdrut JL, Lertora JJ, Batuman V (2007) Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28(9): 1891–1895
89. Saghy E, Payrits M, Helyes Z, Reglodi D, Banki E, Toth G et al (2015) Stimulation of pituitary adenylate cyclase-activating polypeptide (PACAP) in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 47(2):85–92
90. Sismanopoulos N, Delvanis D-A, Alysandratos K-D, Angelidou A, Therianou A, Kalogeromitros D et al (2012) Mast cells in allergic and inflammatory diseases. Curr Pharm Des 18(16):2261–2277